Press Releases

Company press releases and official corporate announcements.

A centralized feed of corporate press releases, earnings announcements, mergers, and official statements. Content is presented for informational purposes and may require additional analysis for market relevance.

Articles

6,781 total articles

Dime to Release Earnings on April 23, 2026

Dime to Release Earnings on April 23, 2026

Dime Community Bancshares, a New York State-chartered trust company with $15 billion in assets and leading deposit market share on Greater Long Island, will release its Q1 2026 earnings on April 23 before U.S. markets open. The CEO will discuss financial results on a conference call with Q&A, accessible via webcast and telephone. A replay will be a…

Kura Oncology Reports Darlifarnib Plus Cabozantinib Demonstrates Robust Activity in Patients With Clear Cell Renal Cell Carcinoma Previously Treated With Cabozantinib

Kura Oncology Reports Darlifarnib Plus Cabozantinib Demonstrates Robust Activity in Patients With Clear Cell Renal Cell Carcinoma Previously Treated With Cabozantinib

Kura Oncology reported encouraging preliminary data from a subset analysis of its ongoing FIT-001 clinical trial combining darlifarnib with cabozantinib in patients with clear cell renal cell carcinoma (ccRCC) previously treated with cabozantinib. The combination demonstrated a 44% objective response rate and 94% disease control rate, with tumor sh…

Immuron Double Digit 3Q Sales Growth

Immuron Double Digit 3Q Sales Growth

Immuron Limited announced unaudited Q3 sales growth of 16% globally for Travelan®, an over-the-counter immunotherapy product targeting gastrointestinal pathogens. Growth was driven by increased brand awareness and marketing in Australia, steady advancements in U.S. sales despite currency headwinds, and significant gains in Canadian retail penetrati…

MiNK Therapeutics Reports Phase II Data on Immune Reprogramming and Durable Survival in PD-1 Refractory Gastroesophageal Cancer

MiNK Therapeutics Reports Phase II Data on Immune Reprogramming and Durable Survival in PD-1 Refractory Gastroesophageal Cancer

MiNK Therapeutics announced Phase II trial results showing their cell therapy agenT-797, combined with botensilimab and balstilimab, achieved a 77% disease control rate and durable survival beyond 20 months in patients with advanced PD-1 refractory gastroesophageal cancer. An induction treatment strategy yielded significant improvements in progress…

Zymeworks Presents New Preclinical Data at AACR 2026 Highlighting Broad Antibody-Drug Conjugate Programs Including Novel RAS-Targeting Platform

Zymeworks Presents New Preclinical Data at AACR 2026 Highlighting Broad Antibody-Drug Conjugate Programs Including Novel RAS-Targeting Platform

Zymeworks Inc. disclosed multiple new preclinical and clinical data sets at the AACR 2026 meeting, highlighting its advanced antibody-drug conjugate (ADC) programs targeting difficult-to-treat cancers, including RAS-mutated tumors. Key presentations showcased efficacy, tumor-selective delivery, and favorable tolerability of novel ADCs such as ZW191…

Zentalis Pharmaceuticals To Present Azenosertib Preclinical Data in Triple-Negative Breast Cancer and Real-World Analysis of Unmet Need in Cyclin E1-Positive Ovarian Cancer at AACR 2026

Zentalis Pharmaceuticals To Present Azenosertib Preclinical Data in Triple-Negative Breast Cancer and Real-World Analysis of Unmet Need in Cyclin E1-Positive Ovarian Cancer at AACR 2026

Zentalis Pharmaceuticals announced encouraging preclinical results for its WEE1 inhibitor, azenosertib, showing efficacy in triple-negative breast cancer (TNBC) models resistant to antibody-drug conjugates. Additionally, real-world data reveal poor outcomes for Cyclin E1-positive ovarian cancer patients under current treatments, emphasizing the unm…

MediaMelon Joins Akamai Qualified Compute Partner Program to Deliver Real-Time Streaming Analytics at Global Scale

MediaMelon Joins Akamai Qualified Compute Partner Program to Deliver Real-Time Streaming Analytics at Global Scale

Akamai Technologies announced that MediaMelon, a streaming intelligence company, has joined its Qualified Compute Partner Program as an Independent Software Vendor. MediaMelon's SmartSight platform, providing real-time video streaming analytics and AI-powered insights, will now be integrated and scaled on Akamai's globally distributed cloud. This p…

Talen Energy Announces Pricing of Senior Notes

Talen Energy Announces Pricing of Senior Notes

Talen Energy Corporation has priced $4 billion in senior notes due 2031 and 2033 to finance its acquisition of 2,451 MW of power generation capacity and redeem existing higher-coupon debt. The move supports the company's expansion with additional fossil and nuclear assets, strengthening its position in the U.S. power generation market.

BioXcel Therapeutics Announces Virtual Event to Discuss Commercial Launch Plan Based on Market Opportunity Assessment for IGALMI® in the At-Home Setting

BioXcel Therapeutics Announces Virtual Event to Discuss Commercial Launch Plan Based on Market Opportunity Assessment for IGALMI® in the At-Home Setting

BioXcel Therapeutics announced a virtual event focused on their commercial launch plan for IGALMI®, targeting the treatment of acute agitation associated with bipolar disorder and schizophrenia in the at-home setting, ahead of the November 14 PDUFA date. Market assessment highlights a significant opportunity with up to 86 million annual addressable…

Pyxis Oncology to Present New Preclinical Data Showing Synergistic Anti-Tumor Activity in a HNSCC model with maMICVO in Combination with Anti-PD-1 at AACR 2026

Pyxis Oncology to Present New Preclinical Data Showing Synergistic Anti-Tumor Activity in a HNSCC model with maMICVO in Combination with Anti-PD-1 at AACR 2026

Pyxis Oncology announced new preclinical data demonstrating that its lead candidate, micvotabart pelidotin (MICVO), a novel antibody-drug conjugate, shows significant anti-tumor activity as monotherapy and synergistic effects when combined with anti-PD-1 therapy in a head and neck squamous cell carcinoma (HNSCC) model. These findings support ongoin…

AOI Expands Its Houston-Area Footprint to 900,000 Square Feet to Increase Capacity and Support Future Growth

AOI Expands Its Houston-Area Footprint to 900,000 Square Feet to Increase Capacity and Support Future Growth

Applied Optoelectronics, Inc. is expanding its Houston-area facilities by adding two adjacent buildings in Pearland, Texas, increasing its manufacturing capacity by about 388,000 square feet. This move supports the company’s ambitious 2027 capacity targets and positions AOI to scale production of high-speed optical transceivers and laser fabricatio…

ORIC® Pharmaceuticals Presents Preclinical Data to Support the Potential of Rinzimetostat Across Prostate Cancer and in Emerging Resistance Settings at the 2026 American Association for Cancer Research (AACR) Annual Meeting

ORIC® Pharmaceuticals Presents Preclinical Data to Support the Potential of Rinzimetostat Across Prostate Cancer and in Emerging Resistance Settings at the 2026 American Association for Cancer Research (AACR) Annual Meeting

ORIC Pharmaceuticals announced the presentation of multiple preclinical data posters at the 2026 AACR Annual Meeting demonstrating the potential of their drug candidate rinzimetostat, an allosteric PRC2 inhibitor, to treat prostate cancer, including treatment-resistant forms. The data indicates strong antitumor activity across prostate cancer model…

Intchains Group Limited Provides Staking Activities Update; Advances Strategic Transformation with AI-Enabled Operating Model to Enhance Efficiency and Productivity

Intchains Group Limited Provides Staking Activities Update; Advances Strategic Transformation with AI-Enabled Operating Model to Enhance Efficiency and Productivity

Intchains Group Limited reports active staking of over 8,000 ETH on multiple platforms to optimize returns from its treasury assets, while undertaking a strategic transformation by embedding AI-enabled tools across its operations to enhance efficiency, streamline costs, and drive innovation in its altcoin mining and Web3 infrastructure services bus…

4DMT Announces New Employment Inducement Grants

4DMT Announces New Employment Inducement Grants

4D Molecular Therapeutics announced equity inducement grants of 67,600 Restricted Stock Units to five new non-executive employees as part of its 2025 Employment Inducement Award Plan. The grants aim to attract talent to support the company’s development of late-stage gene therapies targeting retinal diseases and cystic fibrosis.

USA Rare Earth Appoints Chaitan Kansal as Chief Commercial Officer

USA Rare Earth Appoints Chaitan Kansal as Chief Commercial Officer

USA Rare Earth has appointed Chaitan Kansal as Chief Commercial Officer in a new role to lead global commercial strategy, accelerate customer engagement, and secure long-term offtake agreements. This comes as the company moves from development to active production with recent milestones including commissioning of commercial magnet production and st…

Vera Bradley Terminates Existing Shareholder Rights Plan

Vera Bradley Terminates Existing Shareholder Rights Plan

Vera Bradley, Inc. announced the termination of its existing shareholder rights plan effective April 17, 2026, earlier than the originally scheduled October 11, 2026 expiration. The Board cites a reassessment of control risks through market accumulations and believes the plan is no longer necessary at this time. The company remains committed to pro…

Zhihu Inc. Files Its 2025 Annual Report on Form 20-F

Zhihu Inc. Files Its 2025 Annual Report on Form 20-F

Zhihu Inc., a leading online content community in China, has filed its annual report for the fiscal year ended December 31, 2025, on Form 20-F with the U.S. Securities and Exchange Commission. The report includes audited consolidated financial statements and is accessible on the company’s investor relations website. Zhihu offers free hard copies to…